Adjunctive Peony-Glycyrrhiza Decoction for antipsychotic-induced hyperprolactinemia

Li, Xianbin; Zhao, Lei; Bo, Qijing; Zhou, Fuchun; Li, Bo; Wang, Chuanyue

doi:10.1002/14651858.cd012422

Cited by 1 publication

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several meta-analyses (Li et al, 2013; Zheng et al, 2016) have found that adjunctive aripiprazole may be an effective and safe option for reducing the elevated prolactin induced by APs. A recent Cochrane protocol (Li et al, 2016) on adjunctive PGD for AP-induced hyperprolactinemia suggested that PGD might be a promising treatment strategy to suppress the elevated prolactin level. Consistent with our findings, a previous review (Bo et al, 2016b) which included a RCT (Wu et al, 2012) and two observational trials (Liang, 2013; Shi and Ding, 2013) also found that adjunctive metformin may improve hyperprolactinemia in schizophrenia patients.…”

Section: Discussionmentioning

confidence: 99%

Adjunctive metformin for antipsychotic-related hyperprolactinemia: A meta-analysis of randomized controlled trials

et al. 2017

View full text Add to dashboard Cite

Hyperprolactinemia is a common and severe antipsychotic-induced adverse drug reaction. This meta-analysis of randomized controlled trials systematically examined the efficacy and safety of adjunctive metformin for antipsychotic-related hyperprolactinemia in schizophrenia patients. Two independent investigators searched, extracted, and synthesized data. Weighted mean differences and risk ratios with their 95% confidence intervals were calculated using random effect model. Four randomized controlled trials ( n=509) comparing adjunctive metformin ( n=253) with the control groups ( n=256), lasting 22.7 weeks of treatment, were included in the meta-analysis. The metformin group had significantly lower serum prolactin level at endpoint (four randomized controlled trials, n=501; weighted mean difference: -6.87 ug/L (95% confidence interval: -13.24 to -0.51), p=0.03; I80%) with "moderate quality" based on the grading of recommendations assessment, development, and evaluation system. In patients with menstrual disturbances, the rate of menstruation resumption was 66.7% in the metformin group and 4.8% in the control group. Adverse drug reactions and all-cause discontinuation (three randomized controlled trials, n=339, risk ratio: 0.76 (95% confidence interval: 0.29, 1.97), p=0.57; I= 0%) were similar between the two groups. Adjunctive metformin appears to be effective and safe for reducing antipsychotic-induced hyperprolactinemia and prolactin-related symptoms in schizophrenia patients. Higher quality randomized controlled trials with a large sample size are warranted to confirm these findings.

show abstract